Jeffrey M. Rowe is Director at Zomedica Pharmaceuticals Corp. (ZOM). They have made 4 open-market trades across 2 companies since 2014, most recently 2025-03-17.
CIK 0001619009
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $147K since 2025, against 3 sales. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.